Literature DB >> 28271324

5-HT6 Receptor Agonist and Antagonist Against β-Amyloid-Peptide-Induced Neurotoxicity in PC-12 Cells.

Anand M Bokare1, A K Praveenkumar1, Mandar Bhonde1, Yogendra Nayak2, Ravindra Pal1, Rajan Goel1.   

Abstract

Beta-amyloid peptide (Aβ) induced neurotoxicity is considered as a hallmark of the pathogenesis of Alzheimer's disease (AD). The present study demonstrated the neuroprotective role of 5-HT6 receptors against Aβ-induced neurotoxicity in PC-12 cells. The 5-HT6 receptor agonist EMD-386088 and antagonist SB-399885 were used as pharmacological tools. The NMDA receptor antagonist, memantine, was used as reference standard. The Aβ25-35 (50 µM) induced apoptosis, increased reactive oxygen species (ROS) generation and impaired neurite outgrowth in PC-12 cells. Pre-treatment with 10 µM EMD-386088 and SB-399885 had significantly protected neuronal cell death by maintaining higher cell viability through attenuation of intracellular ROS. Further, both compounds significantly prevented Aβ25-35-induced impairment in neurite outgrowth in PC-12 cells. Similarly, memantine prevented Aβ25-35-induced neurotoxicity in PC-12 cells. These findings suggest that 5-HT6 receptor ligands have protected neurons from Aβ25-35 induced toxicity by reducing ROS and through prevention of impairment in neurite outgrowth. Therefore, 5-HT6 receptor could be an important disease-modifying therapeutic target for AD.

Entities:  

Keywords:  5-HT6 receptor; Alzheimer’s disease; Aβ25−35; Neuroprotection; PC-12 cells

Mesh:

Substances:

Year:  2017        PMID: 28271324     DOI: 10.1007/s11064-017-2217-9

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  25 in total

Review 1.  Mitochondrial regulation of neuronal plasticity.

Authors:  Mark P Mattson
Journal:  Neurochem Res       Date:  2006-10-06       Impact factor: 3.996

Review 2.  An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function.

Authors:  Kevin C F Fone
Journal:  Neuropharmacology       Date:  2008-07-04       Impact factor: 5.250

Review 3.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

Review 4.  5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia.

Authors:  Natasja M W J de Bruin; Chris G Kruse
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 5.  A review on Alzheimer's disease pathophysiology and its management: an update.

Authors:  Anil Kumar; Arti Singh
Journal:  Pharmacol Rep       Date:  2014-09-22       Impact factor: 3.024

6.  The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide.

Authors:  C Kurz; I Ungerer; U Lipka; S Kirr; T Schütt; A Eckert; K Leuner; W E Müller
Journal:  Br J Pharmacol       Date:  2010-03-09       Impact factor: 8.739

Review 7.  5-HT6 receptor memory and amnesia: behavioral pharmacology--learning and memory processes.

Authors:  Alfredo Meneses; Georgina Pérez-García; Teresa Ponce-Lopez; Carlos Castillo
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

8.  The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism.

Authors:  Steven Petratos; Qiao-Xin Li; Amee J George; Xu Hou; Megan L Kerr; Sharon E Unabia; Irene Hatzinisiriou; Danuta Maksel; Marie-Isabel Aguilar; David H Small
Journal:  Brain       Date:  2007-11-13       Impact factor: 13.501

Review 9.  The serotonergic system and cognitive function.

Authors:  Dubravka Švob Štrac; Nela Pivac; Dorotea Mück-Šeler
Journal:  Transl Neurosci       Date:  2016-05-09       Impact factor: 1.757

10.  Redundant Gs-coupled serotonin receptors regulate amyloid-β metabolism in vivo.

Authors:  Jonathan R Fisher; Clare E Wallace; Danielle L Tripoli; Yvette I Sheline; John R Cirrito
Journal:  Mol Neurodegener       Date:  2016-06-18       Impact factor: 14.195

View more
  2 in total

1.  5-HT6 receptor agonist and antagonist modulates ICV-STZ-induced memory impairment in rats.

Authors:  Anand M Bokare; Mandar Bhonde; Rajan Goel; Yogendra Nayak
Journal:  Psychopharmacology (Berl)       Date:  2018-03-03       Impact factor: 4.530

Review 2.  Understanding How Physical Exercise Improves Alzheimer's Disease: Cholinergic and Monoaminergic Systems.

Authors:  Boyi Zong; Fengzhi Yu; Xiaoyou Zhang; Wenrui Zhao; Peng Sun; Shichang Li; Lin Li
Journal:  Front Aging Neurosci       Date:  2022-05-18       Impact factor: 5.702

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.